BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• BioMidwest

  Virtual Radiologic Announces Double Honors From InformationWeek: Ranks #15 on the InformationWeek 500; Innovative Radiology Consult Technology Named One of 2013’s

  September 11, 2013

   · 

  4 min read
• Drug Development

  Kiadis Pharma Completes Five-Year Follow-up of Its Phase I/II Clinical Study With Blood Cancer Product ATIR™ and Study Meets Primary Objective

  September 11, 2013

   · 

  5 min read
• BioForest

  Pharmaceutical Research and Manufacturers of America (PhRMA) Honors Vaccines Pioneers With Research & Hope Awards

  September 11, 2013

   · 

  1 min read
• RedHill Biopharma Ltd. to Present at the Annual BioPharm America International Partnering Conference

  September 11, 2013

   · 

  1 min read
• Lone Star Bio

  Quantum Materials Establishes Milestone as First Company to Deliver Tetrapod Quantum Dot Samples to LCD Display Manufacturer

  September 11, 2013

   · 

  3 min read
• Business

  Dr. Francois Nader, President and CEO of NPS Pharmaceuticals, Inc., Appointed to Biotechnology Industry Organization (BIO)'s Board of Directors

  September 11, 2013

   · 

  1 min read
• BioMidwest

  Case Report Suggests MicroBiome Therapeuitcs’ NM504 May Improve Tolerability of Metformin While Improving Blood Glucose Control

  September 11, 2013

   · 

  4 min read
• BioMidwest

  Galderma Laboratories Release: Jeannette R. Jakus, MD, MBA, Awarded American Academy of Dermatology Translational Biotechnology Fellowship

  September 11, 2013

   · 

  4 min read
• Drug Development

  Topica Pharmaceuticals Presents Interim Safety and Mycologic Results From Its Phase 2b/3 Onychomycosis Trial of 10% Luliconazole Solution at the Interscience Conference on Antimicrobial Agents and Chemotherapy

  September 11, 2013

   · 

  1 min read
• Drug Development

  Durata Therapeutics, Inc. Presents New Pivotal Phase 3 Clinical Results and New In Vitro Data on Dalbavancin at ICAAC

  September 11, 2013

   · 

  1 min read